David-Silva, Aline; Esteves, Joao Victor; Morais, Mychel Raony P. T; Freitas, Helayne Soares; Zorn, Telma Maria; Giannella, Maria Lucia Cardillo Correa 
; Machado, Ubiratan Fabres
Source: Diabetes metabolic syndrome and obesity-targets and therapy. Unidade: FM
Subjects: DIABETES MELLITUS, GLICOSÍDEOS, RATOS, FÍGADO GORDUROSO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DAVID-SILVA, Aline et al. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Diabetes metabolic syndrome and obesity-targets and therapy, v. 13, p. 739-751, 2020Tradução . . Disponível em: https://doi.org/10.2147/DMSO.S242282. Acesso em: 04 nov. 2024.APA
David-Silva, A., Esteves, J. V., Morais, M. R. P. T., Freitas, H. S., Zorn, T. M., Giannella, M. L. C. C., & Machado, U. F. (2020). Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Diabetes metabolic syndrome and obesity-targets and therapy, 13, 739-751. doi:10.2147/DMSO.S242282NLM
David-Silva A, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Giannella MLCC, Machado UF. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice [Internet]. Diabetes metabolic syndrome and obesity-targets and therapy. 2020 ; 13 739-751.[citado 2024 nov. 04 ] Available from: https://doi.org/10.2147/DMSO.S242282Vancouver
David-Silva A, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Giannella MLCC, Machado UF. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice [Internet]. Diabetes metabolic syndrome and obesity-targets and therapy. 2020 ; 13 739-751.[citado 2024 nov. 04 ] Available from: https://doi.org/10.2147/DMSO.S242282
